Results 11 to 20 of about 77,938,455 (214)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome [PDF]

open access: yesInternational Journal of General Medicine, 2016
Brian E Lacy Division of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA Abstract: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide.
Lacy BE
doaj   +6 more sources

Targeted therapies for diarrhea-predominant irritable bowel syndrome

open access: yesClinical and Experimental Gastroenterology, 2012
Irritable bowel syndrome (IBS) causes gastrointestinal symptoms such as abdominal pain, bloating, and bowel pattern abnormalities, which compromise patients' daily functioning. Common therapies address one or two IBS symptoms, while others offer wider symptom control, presumably by targeting pathophysiologic mechanisms of IBS.
Olden KW
openaire   +5 more sources

Management of irritable bowel syndrome with diarrhea [PDF]

open access: yesClínicas de gastroenterología de México (English Edition)
: Irritable bowel syndrome (IBS) with diarrhea (IBS-D) affects ~1% of the general population and is characterized by abdominal pain associated with diarrhea. IBS-D symptoms significantly impact the quality of life of patients. Major uncertainties remain regarding the optimal management of these patients.
Octavio Gómez-Escudero   +1 more
core   +3 more sources

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

open access: yesDrug Design, Development and Therapy, 2017
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related to IBS-D.
Ayşe Elif Özdener, Anastasia Rivkin
openaire   +4 more sources

Treatment of Irritable Bowel Syndrome with Predominant Diarrhea

open access: yesThe Korean Journal of Gastroenterology
Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose stools. Although the precise pathophysiology remains unclear, factors, such as gut microbiota imbalance, visceral ...
Min Cheol Kim   +3 more
doaj   +3 more sources

The Effect of Mesalazine on Pain Management in Patients with Diarrhea-Predominant Irritable Bowel Syndrome [PDF]

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2022
Background and Objective: Irritable bowel syndrome is one of the common gastrointestinal complaints that is often resistant to standard treatment. Since mesalazine reduces abdominal pain and diarrhea through its anti-inflammatory effects, this study was ...
M Khosravi   +3 more
doaj   +1 more source

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review

open access: yesClinical and Experimental Gastroenterology, 2012
Allen W Mangel1, Gareth A Hicks21RTI Health Solutions, Research Triangle Park, NC, 2Tioga Pharmaceuticals Inc, San Diego, CA, USAAbstract: Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel ...
Mangel AW, Hicks GA
doaj   +1 more source

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide

open access: yesInternational Journal of General Medicine, 2017
Apoorva Krishna Chandar1,2 1Department of Gastroenterology and Liver Disease, Case Western Reserve University, 2Digestive Health Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA Abstract: Irritable bowel syndrome (IBS) is a ...
Chandar AK
doaj   +2 more sources

Management of irritable bowel syndrome with diarrhea: focus on eluxadoline [PDF]

open access: yesCurrent Medical Research and Opinion, 2021
We sought to summarize current recommendations for the diagnosis of diarrhea-predominant irritable bowel syndrome (IBS-D) and describe available management options, highlighting a newer US Food and Drug Administration (FDA)-approved agent, eluxadoline.Literature on IBS-D was assessed up to January 2020 using PubMed, with key search terms including "IBS-
Jennifer, Jones   +4 more
openaire   +2 more sources

Is homeopathic treatment more effective than giving time and attention to NHS patients with chronic complaints [PDF]

open access: yes, 2012
Many people seek individualised homeopathic treatment, however its use remains controversial. There have been suggestions that any improvement of the symptoms of those seeking individualised homeopathic treatment is solely down to the time and attention ...
Peckham, Emily Jane
core   +5 more sources

Home - About - Disclaimer - Privacy